FR2673376A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS. - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS. Download PDF

Info

Publication number
FR2673376A1
FR2673376A1 FR9102581A FR9102581A FR2673376A1 FR 2673376 A1 FR2673376 A1 FR 2673376A1 FR 9102581 A FR9102581 A FR 9102581A FR 9102581 A FR9102581 A FR 9102581A FR 2673376 A1 FR2673376 A1 FR 2673376A1
Authority
FR
France
Prior art keywords
compound
pharmaceutical composition
approximately
composition according
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR9102581A
Other languages
French (fr)
Inventor
Lefesvre Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9102581A priority Critical patent/FR2673376A1/en
Priority to PCT/EP1992/000441 priority patent/WO1992015281A1/en
Publication of FR2673376A1 publication Critical patent/FR2673376A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical composition for the treatment of Kaposi's sarcoma. The aim of the invention is to produce a composition for the effective treatment of tumours without the secondary effects of the other known technics. This aim is achieved with the aid of a pharmaceutical composition to the treatment of Kaposi's sarcoma, characterized in that it comprises a first compound of the family of drugs capable of blocking morphine receptors and a second compound facilitating the penetration of the first compound inside the cells of the human body.

Description

COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DES
TUMEURS DE KAPOSI
La présente invention concerne une composition pharmaceutique injectable de préférence par voie intraveineuse et destinée au traitement des tumeurs de Kaposi.PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF
KAPOSI TUMORS
The present invention relates to a pharmaceutical composition which is preferably injectable intravenously and intended for the treatment of Kaposi tumors.

Le sarcome de Kaposi est une affection fréquente en Afrique équatoriale et également dans les pays du bassin méditérranéen, chez les hommes de 40 à 60 ans. Ce cancer peut également survenir chez des personnes dont le système immunitaire est défaillant, par exemple, les malades atteints du SIDA (syndrome d'immuno déficience acquise). Kaposi's sarcoma is a common condition in equatorial Africa and also in the countries of the Mediterranean basin, in men aged 40 to 60 years. This cancer can also occur in people with compromised immune systems, for example, patients with AIDS (acquired immunodeficiency syndrome).

Le syndrome de Kaposi se caractérise par l'apparition sur la peau de taches violacées ou de nodules durs, enchassés dans le derme. Kaposi syndrome is characterized by the appearance on the skin of purplish spots or hard nodules, embedded in the dermis.

Cette éruption s'étend progressivement et entraîne une évolution fatale en quelques mois ou quelques années. This rash gradually spreads and causes a fatal development in a few months or a few years.

Afin de soigner ces tumeurs de Kaposi, on a utilisé jusqu'à présent diverses techniques comme la radiothérapie, la chimiothérapie anti-cancéreuse et l'emploi d'interferons alpha 2B. La radiothérapine donne des résultats intéressants sur le plan esthétique, notamment avec la disparition des taches sur la peau, mais ne soigne pas la maladie proprement dite. In order to treat these Kaposi tumors, various techniques have been used until now, such as radiotherapy, anti-cancer chemotherapy and the use of alpha 2B interferons. Radiation therapy gives interesting results on the esthetic level, in particular with the disappearance of spots on the skin, but does not cure the disease itself.

La chimiothérapie donne également certains résultats partiels mais entraîne des effets secondaires et une toxicite non négligeable. Enfin, l'interfèron alpha 2B ne donne pas de très bons résultats et produit des effets secondaires comme l'apparition de fièvre chez le patient traite. Chemotherapy also gives certain partial results but leads to side effects and considerable toxicity. Finally, the alpha 2B interferon does not give very good results and produces side effects such as the appearance of fever in the patient being treated.

On a egalement préconisé l'emploi de la méthionine enképhaline comme principe actif pour tenter de soigner ce type de cancer, (voir notamment l'article de Zunich. K. et Kirkpatrick. C.H, Journal of
Clin. Immunology, Vol. 8, No 2, 1988).The use of methionine enkephalin has also been recommended as an active ingredient in an attempt to treat this type of cancer (see in particular the article by Zunich. K. and Kirkpatrick. CH, Journal of
Clin. Immunology, Vol. 8, No. 2, 1988).

La méthionine enképhaline est un pentapeptide opioade qui présente non seulement des propriétés analgésiques, anxiolytiques, et anti-dépressives mais également, des propriétés immunomodulatrices en particulier au niveau des lymphocytes.  Methionine enkephalin is an opioad pentapeptide which presents not only analgesic, anxiolytic, and anti-depressive properties but also, immunomodulatory properties in particular in lymphocytes.

Malgré le grand intérêt thérapeutique théorique de la méthionine enképhaline, notamment en ce qui concerne ses propriétés immunomodu latrices, ce produit a été peu utilisé jusqu'à présent. En effet,
Zunich et Kirkpatrick ont conclu que bien que la méthionine enképhaline ait des effets in vitro, elle n'entrainait pas de régression des tumeurs des malades atteints du sarcome de Kaposi.Despite the great theoretical therapeutic interest of methionine enkephalin, in particular with regard to its immunomodulatory properties, this product has been little used until now. Indeed,
Zunich and Kirkpatrick concluded that although methionine enkephalin has effects in vitro, it did not regress tumors in patients with Kaposi's sarcoma.

En conséquence, ce produit a été rejeté par l'homme de l'art qui le considérait comme inefficace pour soigner le sarcome de Kaposi. As a result, this product was rejected by those skilled in the art who considered it ineffective in treating Kaposi's sarcoma.

Le but de la présente invention est de fournir une nouvelle composition pharmaceutique permettant de traiter efficacement les tumeurs de Kaposi, sans presenter les inconvénients des produits ou des techniques de l'art antérieur. The aim of the present invention is to provide a new pharmaceutical composition making it possible to effectively treat Kaposi tumors, without presenting the drawbacks of the products or techniques of the prior art.

A cet effet, l'invention à pour objet une composition pharmaceutique pour le traitement des tumeurs de Kaposi. To this end, the invention relates to a pharmaceutical composition for the treatment of Kaposi tumors.

Selon les caractéristiques de l'invention, ladite composition comprend un premier composé de la famille des produits capables de bloquer les recepteurs à la morphine, et un second composé facilitant la pénétration dudit premier composé à l'intérieur des cellules du corps humain. According to the characteristics of the invention, said composition comprises a first compound from the family of products capable of blocking receptors for morphine, and a second compound facilitating the penetration of said first compound inside the cells of the human body.

En effet, le déposant a constaté par des observations cliniques, que la morphine, utilisée parfois lors de trachéotomies realisées sur des malades atteints du SIDA, aggravait leur état. En conséquence, il a eu l'idée d'utiliser des produits capables de bloquer les récepteurs à la morphine. Toutefois, comme expliqué ci-dessus, ce type de produit, tel que la méthionine enképhaline n'est pas efficace. L'invention consiste donc à associer à un composé de cette famille de produits, un second composé facilitant la pénétration du premier composé dans l'organisme. In fact, the depositor has noted by clinical observations that morphine, sometimes used during tracheostomies performed on patients suffering from AIDS, worsens their condition. Consequently, he came up with the idea of using products capable of blocking morphine receptors. However, as explained above, this type of product, such as methionine enkephalin is not effective. The invention therefore consists in associating with a compound of this family of products, a second compound facilitating the penetration of the first compound into the body.

De façon tout à fait inattendue, on a ainsi découvert que les produits bloquant les récepteurs à la morphine pouvaient soigner efficacement le sarcome de Kaposi. Quite unexpectedly, it was discovered that products blocking morphine receptors could effectively treat Kaposi's sarcoma.

De plus, l'utilisation du second composé permet de diminuer les doses du premier composé tout en ayant de bons résultats cliniques. In addition, the use of the second compound makes it possible to reduce the doses of the first compound while having good clinical results.

L'invention sera mieux comprise à la lecture de la descritpion suivante d'un mode de réalisation de l'invention. The invention will be better understood on reading the following description of an embodiment of the invention.

La composition pharmaceutique selon l'invention comprend donc un premier composé de la famille des produits capables de bloquer les récepteurs à la morphine et un second composé facilitant la pénétration dudit premier composé à l'intérieur des cellules du corps humain. The pharmaceutical composition according to the invention therefore comprises a first compound from the family of products capable of blocking morphine receptors and a second compound facilitating the penetration of said first compound inside the cells of the human body.

Le premier composé est choisi par exemple parmi les enképhalines ou les endorphines et de préférence parmi la leucine enképhaline, la lysine enképhaline ou la méthionine enképhaline. The first compound is chosen, for example, from enkephalins or endorphins and preferably from leucine enkephalin, lysine enkephalin or methionine enkephalin.

Le second compose est choisi par exemple, parmi la carboxyme- thylcellulose, le dioctylsulfosuccinate de sodium ou de préférence le diméthylsulfoxyde (DMSO).  The second compound is chosen, for example, from carboxymethylcellulose, sodium dioctylsulfosuccinate or preferably dimethylsulfoxide (DMSO).

On peut également ajouter à cette composition un troisième composé piégeant les radicaux libres. Ce troisième composé est choisi par exemple parmi la vitamine E, la vitamine C, le gluthation ou de préférence la superoxyde dimutase. One can also add to this composition a third compound trapping free radicals. This third compound is chosen, for example, from vitamin E, vitamin C, gluthation or preferably superoxide dimutase.

La composition selon l'invention comprend
- entre 0,004 et 2 mg environ du premier composé, de préférence entre 0,02 et 0,4 mg environ ou mieux environ 0,1 mg par ml d'une solution comprenant de préférence entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique, ou mieux environ 40% du deuxieme composé et environ 60% d'eau physiologique.The composition according to the invention comprises
- between approximately 0.004 and 2 mg of the first compound, preferably between approximately 0.02 and 0.4 mg or better still approximately 0.1 mg per ml of a solution preferably comprising between 15 and 65% of the second compound and between 85 and 35% of physiological water, or better still about 40% of the second compound and about 60% of physiological water.

Lorsque la composition pharmaceutique selon l'invention comprend un troisième composé piegeant les radicaux libres, elle en comprend - de préférence entre 8-10 4 mg et 2-10 2 mg ou mieux environ 0,004 mg par ml d'une solution comprenant de préférence entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique ou mieux environ 40% du deuxième composé et environ 60% d'eau physiologique. When the pharmaceutical composition according to the invention comprises a third free radical scavenging compound, it comprises - preferably between 8-10 4 mg and 2-10 2 mg or better still approximately 0.004 mg per ml of a solution preferably comprising between 15 and 65% of the second compound and between 85 and 35% of physiological water or better still approximately 40% of the second compound and approximately 60% of physiological water.

Un exemple de préparation va maintenant être décrit
Exemple 1
On mélange 25 mg de méthionine en képhaline et eventuellement 1 mg de superoxyde dimutase dans 100 ml de DMSO et 150 ml d'eau physiologique.An example of preparation will now be described.
Example 1
25 mg of methionine are mixed in kephalin and optionally 1 mg of superoxide dimutase in 100 ml of DMSO and 150 ml of physiological water.

Le mélange est alors sterilisé à froid, par filtration sur un filtre réalisé en un materiau non sensible aux produits utilisés. The mixture is then sterilized in the cold, by filtration on a filter made of a material not sensitive to the products used.

Le mode d'administration est le suivant
La composition precédente est administrée au patient sous forme d'une injection intraveineuse lente ou d'une perfusion intraveineuse dans du sérum salé isotonique, à raison de 2,5 ml au rythme d'une injection quotidienne pendant 15 jours, puis deux injections par semaine pendant 2 mois.The method of administration is as follows
The above composition is administered to the patient in the form of a slow intravenous injection or an intravenous infusion in isotonic saline, at a rate of 2.5 ml at the rate of a daily injection for 15 days, then two injections per week. during 2 months.

A l'issu d'un mois de traitement, on a observé chez les patients une disparition quasi complète des taches noires des tumeurs cutanées de Kaposi et des oedèmes qui les accompagnent ainsi qu'une disparition de la dyspnée chez les malades présentant un Kaposi pulmonaire. On a également observé une nette amélioration de l'as thénie et de l'état général des malades. Toutefois, ces améliorations nécessitent un traitement d'entretien pour que les symptomes ne réapparaissent pas. At the end of a month of treatment, the patients observed an almost complete disappearance of the black spots from the Kaposi skin tumors and the edemas which accompany them, as well as a disappearance of dyspnea in patients with pulmonary Kaposi. . There has also been a marked improvement in asthenia and the general condition of the patients. However, these improvements require maintenance treatment so that symptoms do not recur.

Il semble que l'addition de la superoxyde dimutase permette d'obtenir les memes résultats cliniques plus rapidement.  It seems that the addition of superoxide dimutase makes it possible to obtain the same clinical results more quickly.

Claims (16)

REVENDICATIONS 1. Composition pharmaceutique pour le traitement des tumeurs de 1. Pharmaceutical composition for the treatment of tumors of Kaposi, caractérisée en ce qu'elle comprend un premier composé de la famille des produits capables de bloquer les récepteurs à la morphine, et un deuxième composé facilitant la pénétration dudit premier composé à l'intérieur des cellules du corps humain.Kaposi, characterized in that it comprises a first compound from the family of products capable of blocking morphine receptors, and a second compound facilitating the penetration of said first compound inside the cells of the human body. 2. Composition pharmaceutique selon la revendication 1, caractérisée en ce que le premier composé est choisi parmi les enképhalines ou les endorphines. 2. Pharmaceutical composition according to claim 1, characterized in that the first compound is chosen from enkephalins or endorphins. 3. Composition pharmaceutique selon la revendication 1, caractérisee en ce que le premier composé est choisi parmi la leucine enképhaline, la lysine enképhaline ou la méthionine enképhaline. 3. Pharmaceutical composition according to claim 1, characterized in that the first compound is chosen from leucine enkephalin, lysine enkephalin or methionine enkephalin. 4. Composition pharmaceutique selon la revendication 1, caractérisée en ce que le deuxième composé est choisi parmi le diméthylsulfoxyde, la carboxyméthylcellulose de sodium ou le dioctylsulfosuccinate de sodium. 4. Pharmaceutical composition according to claim 1, characterized in that the second compound is chosen from dimethylsulfoxide, sodium carboxymethylcellulose or sodium dioctylsulfosuccinate. 5. Composition pharmaceutique selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend entre 0.004 et 2 mg environ du premier composé pour 1 ml d'une solution comprenant entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique. 5. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises between 0.004 and 2 mg approximately of the first compound for 1 ml of a solution comprising between 15 and 65% of the second compound and between 85 and 35 % physiological water. 6. Composition pharmaceutique selon la revendication 5, caractérisée en ce qu'elle comprend entre 0.004 et 2 mg environ du premier composé pour 1 ml d'une solution comprenant environ 40% du deuxième composé et environ 60% d'eau physiologique. 6. Pharmaceutical composition according to claim 5, characterized in that it comprises between 0.004 and 2 mg approximately of the first compound for 1 ml of a solution comprising approximately 40% of the second compound and approximately 60% of physiological water. 7. Composition pharmaceutique selon la revendication 5, caractérisée en ce qu'elle comprend entre 0,02 et 0,4 mg environ du premier composé pour 1 ml d'une solution comprenant entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique. 7. Pharmaceutical composition according to claim 5, characterized in that it comprises between 0.02 and 0.4 mg approximately of the first compound for 1 ml of a solution comprising between 15 and 65% of the second compound and between 85 and 35 % physiological water. 8. Composition pharmaceutique selon la revendication 7, caractérisée en ce qu'elle comprend entre 0,02 et 0,4 mg environ du premier composé pour 1 ml d'une solution comprenant environ 40% du deuxième composé et environ 60% d'eau physiologique. 8. Pharmaceutical composition according to claim 7, characterized in that it comprises between 0.02 and 0.4 mg approximately of the first compound for 1 ml of a solution comprising approximately 40% of the second compound and approximately 60% of water physiological. 9. Composition pharmaceutique selon la revendication 7, caractérisée en ce qu'elle comprend environ 0,1 mg du premier composé pour 1 ml d'une solution comprenant entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique. 9. Pharmaceutical composition according to claim 7, characterized in that it comprises approximately 0.1 mg of the first compound for 1 ml of a solution comprising between 15 and 65% of the second compound and between 85 and 35% of physiological water . 10. Composition pharmaceutique selon la revendication 9, caractérisee en ce qu'elle comprend environ 0,1 mg du premier composé pour 1 ml d'une solution comprenant environ 40% du deuxième composé et environ 60% d'eau physiologique. 10. Pharmaceutical composition according to claim 9, characterized in that it comprises approximately 0.1 mg of the first compound for 1 ml of a solution comprising approximately 40% of the second compound and approximately 60% of physiological water. 11. Compositon pharmaceutique selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend un troi sième compose piégeant les radicaux libres. 11. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises a third compound trapping free radicals. 12. Composition pharmaceutique selon la revendication 11, caractérisee en ce que le troisième composé piégeant les radicaux libres est choisi parmi la superoxyde dimutase, la vitamine E, la vitamine 12. Pharmaceutical composition according to claim 11, characterized in that the third compound scavenging free radicals is chosen from superoxide dimutase, vitamin E, vitamin C ou le glutathion.C or glutathione. 13. Composition pharmaceutique selon la revendication 5, 7 ou 9, caractérisée en ce qu'elle comprend entre 8{10 4 mg et 2.102 mg d'un composé piégeant les radicaux libres pour 1 ml d'une solution comprenant entre 15 et 65% du deuxieme composé et entre 85 et 35% d'eau physiologique. 13. Pharmaceutical composition according to claim 5, 7 or 9, characterized in that it comprises between 8 {10 4 mg and 2.102 mg of a compound scavenging free radicals for 1 ml of a solution comprising between 15 and 65% of the second compound and between 85 and 35% of physiological water. 14. Composition pharmaceutique selon la revendication 6, 8 ou 10, caractérisée en ce qu'elle comprend entre 8-10 4 mg et 2-10 2 mg dtun composé piégeant les radicaux libres pour 1 ml d'une solution comprenant environ 40% du deuxième composé et environ 60% d'eau physiologique. 14. Pharmaceutical composition according to claim 6, 8 or 10, characterized in that it comprises between 8-10 4 mg and 2-10 2 mg of a compound scavenging free radicals for 1 ml of a solution comprising approximately 40% of the second compound and about 60% physiological water. 15. Composition pharmaceutique selon la revendication 13, caractérisée en ce qu'elle comprend environ 0,004 mg d'un composé piégeant les radicaux libres pour 1 ml d'une solution comprenant entre 15 et 65% du deuxième composé et entre 85 et 35% d'eau physiologique. 15. Pharmaceutical composition according to claim 13, characterized in that it comprises approximately 0.004 mg of a compound scavenging free radicals for 1 ml of a solution comprising between 15 and 65% of the second compound and between 85 and 35% d physiological water. 16. Composition pharmaceutique selon la revendication 14, caractérisée en ce qu'elle comprend environ 0,004 mg d'un composé piégeant les radicaux libres pour 1 ml d'une solution comprenant environ 40% du deuxième composé et environ 60% d'eau physiologique.  16. Pharmaceutical composition according to claim 14, characterized in that it comprises approximately 0.004 mg of a compound scavenging free radicals for 1 ml of a solution comprising approximately 40% of the second compound and approximately 60% of physiological water.
FR9102581A 1991-03-01 1991-03-01 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS. Pending FR2673376A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9102581A FR2673376A1 (en) 1991-03-01 1991-03-01 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS.
PCT/EP1992/000441 WO1992015281A1 (en) 1991-03-01 1992-02-28 Pharmaceutical composition for the treatment of kaposi's sarcoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102581A FR2673376A1 (en) 1991-03-01 1991-03-01 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS.

Publications (1)

Publication Number Publication Date
FR2673376A1 true FR2673376A1 (en) 1992-09-04

Family

ID=9410323

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9102581A Pending FR2673376A1 (en) 1991-03-01 1991-03-01 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS.

Country Status (2)

Country Link
FR (1) FR2673376A1 (en)
WO (1) WO1992015281A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181001A2 (en) * 1984-11-09 1986-05-14 Eisai Co., Ltd. Polypeptide, a process for preparing the same, a pharmaceutical composition containing said polypeptide as well as the use thereof
EP0341661A2 (en) * 1988-05-11 1989-11-15 The Du Pont Merck Pharmaceutical Company Peptide-drug compositions containing alpha-aminoboronic acid derivatives
JPH0232028A (en) * 1988-07-19 1990-02-01 Rooman Kogyo:Kk Antitussive agent
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181001A2 (en) * 1984-11-09 1986-05-14 Eisai Co., Ltd. Polypeptide, a process for preparing the same, a pharmaceutical composition containing said polypeptide as well as the use thereof
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
EP0341661A2 (en) * 1988-05-11 1989-11-15 The Du Pont Merck Pharmaceutical Company Peptide-drug compositions containing alpha-aminoboronic acid derivatives
JPH0232028A (en) * 1988-07-19 1990-02-01 Rooman Kogyo:Kk Antitussive agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DERWENT WPIL, accession no. 90-079189 [11], Derwent Publications Ltd, Londres, GB; & JP-A-2 032 028 (ROMAN KOGYO K.K.) 01-02-1990 *

Also Published As

Publication number Publication date
WO1992015281A1 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
CN103327986B (en) Comprising the treatment using magnetic dipole stabilizing solutions or improve disease and enhance the method for performance
RU2070722C1 (en) Method of treatment of mammalian with gastroenteric tract ulcer disease and pharmcomposition for its realization
MXPA01004980A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby.
CZ308996A3 (en) Combination of dosing amounts of a pharmaceutical preparation for treating cancer in human, use of the dosing amount of a medicament against cancer and hyaluronic acid and pharmaceutical preparations
EP1871399A2 (en) Use of lecithin as a medicament for treating psoriasis
IT8922725A1 (en) USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY
KR940018089A (en) Prevention and treatment for radiation damage of internal tissue
FR2508797A1 (en) MEDICINAL PRODUCT COMPRISING THE REACTION OF A C1 TO C6 CARBOXYLIC ACID ON A BASIC AMINO ACID
DE60116075T4 (en) TREATMENT OF TUMORS WITH PHOTODYNAMIC THERAPY
JP2011506467A (en) Method of treatment of melanoma with alpha thymosin peptide combined with antineoplastic heat shock apoptosis activator (HSAA)
US3560612A (en) Method of alleviating hypercitricemia
WO2021099453A1 (en) Aqueous liquid extract of spirulina for preventing and/or treating peripheral chemotherapy-induced neuropathies and the symptoms thereof, and corresponding composition and use
CA2018630A1 (en) Use of a polypeptide having human interleukine 2 activity to prepare a pharmaceutical compound for the treatment of primary cancer of the plevra
JPH01261334A (en) Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof
FR2673376A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KAPOSI TUMORS.
DE2740953A1 (en) USE OF PROSTAGLANDINES TO LOWER BLOOD SUGAR LEVELS
FUJIMOTO et al. Mitomycin C carrying microspheres as a novel method of drug delivery
CA2654956C (en) Peptides with anti-proliferative activity
EP1368027B1 (en) Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors
Burrows et al. Reactivation of scabies rash by methotrexate
KR20210039414A (en) Combination therapy for the treatment of cancer
EP0402208A1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
EP0000124A1 (en) Composition for lowering the blood-sugar level and for improving the blood flow and the wound healing
CA2140445A1 (en) Procede d'administration de solutions de facteur de stimulation des colonies granulocytaires
RU2077319C1 (en) Method of psoriasis treatment